MX353589B - Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina. - Google Patents

Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.

Info

Publication number
MX353589B
MX353589B MX2013014935A MX2013014935A MX353589B MX 353589 B MX353589 B MX 353589B MX 2013014935 A MX2013014935 A MX 2013014935A MX 2013014935 A MX2013014935 A MX 2013014935A MX 353589 B MX353589 B MX 353589B
Authority
MX
Mexico
Prior art keywords
antibody
purine analog
combination therapy
purine
analog
Prior art date
Application number
MX2013014935A
Other languages
English (en)
Spanish (es)
Other versions
MX2013014935A (es
Inventor
Rojkjaer Lisa
Winderlich Mark
Steidl Stefan
Krohn Susanne
Amersdorffer Jutta
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2013014935A publication Critical patent/MX2013014935A/es
Publication of MX353589B publication Critical patent/MX353589B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2013014935A 2011-08-16 2012-08-14 Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina. MX353589B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Publications (2)

Publication Number Publication Date
MX2013014935A MX2013014935A (es) 2014-07-09
MX353589B true MX353589B (es) 2018-01-19

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014935A MX353589B (es) 2011-08-16 2012-08-14 Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.

Country Status (25)

Country Link
US (3) US20140227277A1 (cg-RX-API-DMAC7.html)
EP (2) EP4083071A3 (cg-RX-API-DMAC7.html)
JP (1) JP6114273B2 (cg-RX-API-DMAC7.html)
KR (3) KR20200060779A (cg-RX-API-DMAC7.html)
CN (1) CN103703027B (cg-RX-API-DMAC7.html)
AU (1) AU2012296905B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013033916B1 (cg-RX-API-DMAC7.html)
CA (1) CA2841738C (cg-RX-API-DMAC7.html)
CY (1) CY1125148T1 (cg-RX-API-DMAC7.html)
DK (1) DK2744826T3 (cg-RX-API-DMAC7.html)
ES (1) ES2909720T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220224T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058855T2 (cg-RX-API-DMAC7.html)
IL (1) IL230295B (cg-RX-API-DMAC7.html)
LT (1) LT2744826T (cg-RX-API-DMAC7.html)
MX (1) MX353589B (cg-RX-API-DMAC7.html)
PL (1) PL2744826T3 (cg-RX-API-DMAC7.html)
PT (1) PT2744826T (cg-RX-API-DMAC7.html)
RS (1) RS63121B1 (cg-RX-API-DMAC7.html)
RU (1) RU2664462C9 (cg-RX-API-DMAC7.html)
SG (1) SG10201606788VA (cg-RX-API-DMAC7.html)
SI (1) SI2744826T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200160T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013024095A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201401835B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
CA2951427A1 (en) * 2014-06-16 2015-12-23 Xencor, Inc. Treatment for chronic lymphocytic leukemia (cll)
CA2986175A1 (en) * 2015-05-26 2016-12-01 Morphosys Ag Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
MA45124B1 (fr) * 2016-05-30 2021-05-31 Morphosys Ag Procédés permettant de prédire un bénéfice thérapeutique d'une thérapie anti-cd19 chez des patients
IL266216B2 (en) * 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
PL3630177T3 (pl) * 2017-05-31 2024-04-08 Morphosys Ag Paradygmat leczenia dla leczenia skojarzonego przeciwciałem anty-cd19 i wenetoklaksem
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
KR20240131370A (ko) * 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임
WO2025012080A1 (en) 2023-07-13 2025-01-16 Christian-Albrechts-Universität Zu Kiel Humanized anti-cd7 antibody

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US11852A (en) 1854-10-31 Abraham bassford
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP1648512A4 (en) 2003-07-31 2009-01-21 Immunomedics Inc ANTI-CD19 ANTIBODIES
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
MX2007015944A (es) 2005-06-20 2008-03-07 Medarex Inc Anticuerpos cd19 y sus usos.
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
AU2006332155B2 (en) * 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
CA2662340C (en) 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
RU2012109451A (ru) * 2009-08-14 2013-09-27 Роше Гликарт Аг Комбинированная терапия на основе афукозилированного антитела к cd20 в сочетании с флударабином и/или митоксантроном
EP2501237A1 (en) * 2009-11-06 2012-09-26 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
HRP20220224T1 (hr) 2022-04-29
RS63121B1 (sr) 2022-05-31
DK2744826T3 (da) 2022-03-28
BR112013033916A2 (pt) 2017-11-28
US20200352975A1 (en) 2020-11-12
ZA201401835B (en) 2015-06-24
RU2664462C2 (ru) 2018-08-17
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
KR20140071368A (ko) 2014-06-11
PL2744826T3 (pl) 2022-05-30
ES2909720T3 (es) 2022-05-10
WO2013024095A1 (en) 2013-02-21
KR102117202B1 (ko) 2020-06-01
EP2744826B1 (en) 2022-02-09
CN103703027A (zh) 2014-04-02
EP2744826A1 (en) 2014-06-25
US20240424012A1 (en) 2024-12-26
HUE058855T2 (hu) 2022-09-28
PT2744826T (pt) 2022-05-19
CA2841738A1 (en) 2013-02-21
NZ617771A (en) 2016-01-29
CY1125148T1 (el) 2024-12-13
EP4083071A3 (en) 2023-02-22
SMT202200160T1 (it) 2022-05-12
AU2012296905B2 (en) 2017-01-05
IL230295B (en) 2018-03-29
JP2014525925A (ja) 2014-10-02
EP4083071A2 (en) 2022-11-02
RU2014103490A (ru) 2015-09-27
JP6114273B2 (ja) 2017-04-12
CA2841738C (en) 2022-12-06
RU2664462C9 (ru) 2018-09-28
KR20190094478A (ko) 2019-08-13
SI2744826T1 (sl) 2022-05-31
BR112013033916B1 (pt) 2022-11-16
KR20200060779A (ko) 2020-06-01
LT2744826T (lt) 2022-04-25
US20140227277A1 (en) 2014-08-14
CN103703027B (zh) 2018-01-12

Similar Documents

Publication Publication Date Title
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
MX2013014933A (es) Terapia de combinacion con un anticuerpo anti-cd19 y una mostaza de nitrogeno.
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
CA143819S (en) Intravenous line organizer
CA144920S (en) Bottle
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
CA141065S (en) Dual c clip
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
CA141284S (en) Bracket
CA144349S (en) Chair side member
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CA143991S (en) Dual function wine device
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
TN2013000472A1 (en) Induction of immune tolerance by using methotrexate
MX2022016270A (es) Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
CA141066S (en) Dual c clip
MX2022006154A (es) Combinaciones y sus usos.
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
GB201208362D0 (en) Fixing system
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
CA141929S (en) Retainer for railings
GB2594662B (en) Absorbent articles with curved elasticized laminates
UA70775U (ru) Способ лечения менингококцемии у детей
GB2594220B (en) Absorbent articles with curved elasticized laminates

Legal Events

Date Code Title Description
FG Grant or registration